Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients

• Published in: EBioMedicine Vol. 42; pp. 76 - 85
• Main Authors: James, Judith A., Chen, Hua, Young, Kendra A., Bemis, Elizabeth A., Seifert, Jennifer, Bourn, Rebecka L., Deane, Kevin D., Demoruelle, M. Kristen, Feser, Marie, O'Dell, James R., Weisman, Michael H., Keating, Richard M., Gaffney, Patrick M., Kelly, Jennifer A., Langefeld, Carl D., Harley, John B., Robinson, William, Hafler, David A., O'Connor, Kevin C., Buckner, Jane, Guthridge, Joel M., Norris, Jill M., Holers, V. Michael
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2019; Elsevier
• Subjects: Adult; Aged; Alleles; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - etiology; Autoantibodies; Autoantibodies - immunology; Autoimmunity - genetics; Environment; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic risk; Humans; Lupus; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - etiology; Male; Middle Aged; Nuclear Family; Organ Specificity - immunology; Polymorphism, Single Nucleotide; Relatives; Research paper; Rheumatoid arthritis; Risk Factors; Type I diabetes; Lupus; Type I diabetes; Relatives; Genetic risk; Autoantibodies; Rheumatoid arthritis
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2019.03.063

Autoimmune disease prevention requires tools to assess an individual's risk of developing a specific disease. One tool is disease-associated autoantibodies, which accumulate in an asymptomatic preclinical period. However, patients sometimes exhibit autoantibodies associated with a different disease classification. When and how these alternative autoantibodies first appear remain unknown. This cross-sectional study characterizes alternative autoimmunity, and associated genetic and environmental factors, in unaffected first-degree relatives (FDRs) of patients, who exhibit increased future risk for the same disease. Samples (n = 1321) from disease-specific autoantibody-positive (aAb+) systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and type 1 diabetes (T1D) patients; and unaffected aAb+ and autoantibody-negative (aAb–) SLE and RA FDRs were tested for SLE, RA, and T1D aAbs, as well as anti-tissue transglutaminase, anti-cardiolipin and anti-thyroperoxidase. FDR SLE and RA genetic risk scores (GRS) were calculated. Alternative autoimmunity occurred in SLE patients (56%) and FDRs (57·4%), RA patients (32·6%) and FDRs (34·8%), and T1D patients (43%). Expanded autoimmunity, defined as autoantibodies spanning at least two other diseases, occurred in 18·5% of SLE patients, 16·4% of SLE FDRs, 7·8% of RA patients, 5·3% of RA FDRs, and 10·8% of T1D patients. SLE FDRs were more likely to have alternative (odds ratio [OR] 2·44) and expanded (OR 3·27) autoimmunity than RA FDRs. Alternative and expanded autoimmunity were associated with several environmental exposures. Alternative autoimmunity was associated with a higher RA GRS in RA FDRs (OR 1·41), and a higher SLE GRS in aAb+ RA FDRs (OR 1·87), but not in SLE FDRs. Autoimmunity commonly crosses disease-specific boundaries in systemic (RA, SLE) and organ-specific (T1D) autoimmune diseases. Alternative autoimmunity is more common in SLE FDRs than RA FDRs, and is influenced by genetic and environmental factors. These findings have substantial implications for preclinical disease pathogenesis and autoimmune disease prevention studies. NIH U01AI101981, R01AR051394, U19AI082714, P30AR053483, P30GM103510, U54GM104938, U01AI101934, R01AI024717, U01AI130830, I01BX001834, & U01HG008666.